by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Bio Technology : October 2009
Volume 19 • Number 3 • October 2009 Australasian BioTechnology 73 AusBioINTERNATIONAL Some UK companies attending AusBiotech 2009 M-Scan primarily operates in the fields of biopharmaceutical, pharmaceutical, industrial, environmental and forensic chemical analysis and is a world-leading contract research, analytical services, consultancy and training company. While based in the UK, M-Scan also has laboratories in the USA, Switzerland and Germany and offices in Europe, India, Singapore and South Korea. Veeda specialises in the early clinical development of drugs and has facilities in the UK, India, Malaysia and Belgium. This gives their clients access to the vast popu- lations and economies of Asia combined with an experi- enced UK project management service. PanGenetics is a therapeutic antibody development company that specialises in taking antibodies from the late research stage through to clinical proof-of-concept. The most advanced programmes of PanGenetics are PG102, a CD40 antagonist that is being evaluated in a clinical study for use in autoimmune indications, and PG110, an anti-nerve growth factor antibody for use in chronic pain. RML Pharma is a consultancy specialising in the devel- opment of early phase assets and experts in chemistry, manufacturing and controls (CMC) activities. RML most often helps companies with project management, route selection and development, physicochemical studies, product development, risk management and regulatory submissions. CambridgeIP is a business intelligence provider to the health and life sciences sector. Its proprietary methods and tools leverage leading edge data mining and data analysis techniques to provide clients with critical infor- mation and advice. Cambridge is currently working on a project to centralise all data related to stem cell inven- tions -- the project combines semi-automated patent data analysis with data from research publications, clinical trials and litigations. Cambridge will be looking for potential Australian partners and collaborators for this and other life science initiatives. Inocul8 focuses on the translation of world-leading aca- demic research into high impact vaccines for livestock. The company works alongside the Moredun Research Institute to enhance the capacity in the development of vaccines and to act as a route for commercial develop- ment of emerging technologies. Inocul8 are looking for partners to work with for the further development, manu- facture and distribution of new livestock vaccines. IP Pragmatics is an IP asset management company that has been running the InterAct project since 2005. InterAct is a unique partnership between six leading UK govern- ment research organisations, that was established to capture the synergies derived through combining the IP, know-how and R&D services of these multi-disciplinary institutes. It has proved to be a successful way to com- mercialise government research across different business fields that include agriculture, food, human health and the environment. Of course this is merely a sample of the companies coming to AusBiotech, the full delegation will also include key representatives from the UK's scientific and academic communities. The UK government recognises that a close working relationship between research and business is crucial in developing the critical mass of skills and infra- structure required to accelerate the discovery and develop- ment of new medicines. The UK's global presence in life sciences is founded on the abilities of its universities and research centres. As an example, the UK has been awarded over 20 Nobel Prizes in life sciences and Cambridge University has received more Nobel Prizes than any other organisation around the world. It's no coincidence that this academic excellence has translated into a strong market presence, with one-fifth of all medicines being sold around the world developed in the UK and 35% of Europe's biopharmaceuti- cal clinical trials take place in Britain. Some of these top researchers will be heading to Australia to showcase UK biotechnology R&D excellence. The delegation will include specialists in stem cells, cancer, diabetes, neuroscience and bioinformatics, people like Professor Chris Hewitt, Director of the EPSRC Doctoral Training Centre for Regenerative Medicine who is heading to Australia to discuss research capabilities, collaborate with Australian colleagues and look for opportunities to build joint partnerships. Despite the global economic downturn, the future for biotechnology looks bright, and opportunities abound for companies with great ideas and even better products. UK Trade & Investment Sector Champion, Jon Mowles, brings 30 years' experience working in the life sciences sector to internationalise and contribute to the prosperity of the UK.